Stockscreener 앱 받기
551.25
1.24%
6.74
시간 외 거래:
551.25
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MDGL Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Madrigal Pharmaceuticals, Inc. Revenue Breakdown – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553 - Moomoo
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares By Investing.com - Investing.com Australia
UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669 - Moomoo
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal New Hires Receive Options With $550.25 Exercise Price - Stock Titan
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Form 144 Madrigal Pharmaceuticals For: 21 July By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares - Investing.com
Madrigal Pharmaceuticals (MDGL) insider files Form 144 for 2,500-share sale - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 22.65% Potential Upside - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (MDGL) Edition - Stock Traders Daily
Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739 - Moomoo
Citizens raises Madrigal Pharmaceuticals price target on lower tax assumptions - Investing.com Nigeria
Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30 - Stock Titan
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 - The Manila Times
Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings? - Sahm
Guojin Securities: The MASH sector is seeing intensive, multi‑dimensional catalysts come to fruition, and Madrigal is expected to maintain double-digit growth over the long term. - Moomoo
Lobbying Update: $120,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed | MDGL Stock News - Quiver Quantitative
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542 - Moomoo
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Pipeline Moves - Yahoo Finance
Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says - Moomoo
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio - BioBuzz
Madrigal receives three new U.S. patents for resmetirom drug - Investing.com
Madrigal receives three new U.S. patents for resmetirom drug By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals (MDGL) Secures New Patents to Enhance I - GuruFocus
New Rezdiffra patents extend Madrigal’s MASH IP into cirrhosis care - Stock Titan
Madrigal Grants Equity Awards to Seven New Employees - MyChesCo
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Unpacking a 26.46% Potential Upside - DirectorsTalk Interviews
Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down - Quiver Quantitative
3 Under-the-Radar Stocks to Buy and Hold - Yahoo Finance
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Insider Monkey
5 Best Under-the-Radar Stocks to Invest In - Insider Monkey
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Navigating a Promising 28.52% Upside Potential - DirectorsTalk Interviews
Madrigal gives seven new employees stock awards to join the company - Stock Titan
MDGLMadrigal Pharmaceuticals Inc Latest SEC Filings - Finviz
Ribocure and Madrigal nominate siRNA drug candidate for MASH - BioWorld News
Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Lelezard
Madrigal and Ribo start IND-enabling studies after MASH milestone - Stock Titan
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating - Investing.com
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $900 - Moomoo
Price to earnings forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Madrigal Pharmaceuticals, Inc.(NasdaqGS:MDGL) added to Russell 1000 Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
1.97%
0.83%
자본화:
|
볼륨(24시간):